Invest for a Sustainable Future, Impact Capital Asset Management

ICAM

Established in August 2020, Impact Capital Asset Management Pte. Ltd. (ICAM) was conceived by seasoned professionals Deepak Mawandia and Atul Tetambe. Both have accumulated a wealth of knowledge and experience from their extensive tenures in the financial sector. In 2019, ICAM secured its RFMC license and subsequently introduced a technology-centric venture fund. By 2021, with the acquisition of its CMS license, ICAM witnessed steady growth in its assets under management.

Presently, ICAM manages a portfolio exceeding USD 1 billion, diversified across various countries. Central to ICAM’s foundation is a commitment to offering a platform singularly dedicated to the best interests of its investor clients. The combined expertise of Deepak and Atul firmly establishes ICAM as a notable entity in the wealth management field.

Invest for a Sustainable Future

Impact Capital Asset Management

Established in August 2020, Impact Capital Asset Management Pte. Ltd. (ICAM) was conceived by seasoned professionals Deepak Mawandia and Atul Tetambe. Both have accumulated a wealth of knowledge and experience from their extensive tenures in the financial sector. In 2019, ICAM secured its RFMC license and subsequently introduced a technology-centric venture fund. By 2021, with the acquisition of its CMS license, ICAM witnessed steady growth in its assets under management. Presently, ICAM manages a portfolio exceeding USD 1 billion, diversified across various countries. Central to ICAM’s foundation is a commitment to offering a platform singularly dedicated to the best interests of its investor clients. The combined expertise of Deepak and Atul firmly establishes ICAM as a notable entity in the wealth management field.

Equity Bottom-Up

<ul><li>China Medical System (CMS) entered FY2025 with a clearer strategic direction than it had at initiation.</li><li>The earlier debate was whether the company could move through the volume-based procurement (VBP) shock and rebuild growth through innovative and non-VBP exclusive products.</li><li>FY2025 largely answered that question on the revenue line. </li></ul>

China Medical System (CMS) entered FY2025 with a clearer strategic direction than it had at initiation.The earlier debate was whether the company could move through the volume-based procurement (VBP) shock and rebuild growth through innovative and non-VBP exclusive products.FY2025 largely answered that question on the revenue line. 

China Medical System Holdings Limited: Earnings Update